Sofosbuvir 400 mg / velpatasvir 100 mg Oral Tablet
RxNorm 1799212
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 1799212 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: sofosbuvir 400 mg / velpatasvir 100 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SCDPrescribable
Semantic Clinical Drug (SCD):
Sofosbuvir 400 mg / velpatasvir 100 mg Oral Tablet
(Atom ID: 8233924)
FNPrescribable
Full form of descriptor (FN):
Product containing precisely sofosbuvir 400 mg and velpatasvir 100 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 12537707)
PSNPrescribable
Prescribable Name (PSN):
Sofosbuvir 400 mg / velpatasvir 100 mg Oral Tablet
(Atom ID: 8233933)
PTPrescribable
Designated preferred name (PT):
Sofosbuvir 400 mg and velpatasvir 100 mg oral tablet
(Atom ID: 12537883)
Patient Education
Sofosbuvir and Velpatasvir
The combination of sofosbuvir and velpatasvir is used alone or with ribavirin (Copegus, Rebetol, Ribasphere) to treat chronic hepatitis C (an ongoing viral infection that damages the liver) in adults and children 6 years of age and older or who weigh at least 37 lbs (17 kg). Sofosbuvir is in a class of antiviral medications called nucleotide hepatitis C virus (HCV) NS5B polymerase inhibitors. Velpatasvir is in a class of antiviral medications called HCV NS5A replication complex inhibitors. The combination of sofosbuvir and velpatasvir works by stopping the virus that causes hepatitis C from spreading inside the body.
[Learn More]
* Please review the disclaimer below.